Citigroup: Sanofi's Dupixent Faces Competitive Threats

By: news.futunn.com|11/13/2026 08:23:22

Citigroup analysts point out that Sanofi's best-selling drug Dupixent may face competition in the coming years from AstraZeneca's tozorakimab, Pfizer's tilrekimig, and AbbVie and Apogee's zumilokibart. Dupixent, developed jointly by Sanofi and Regeneron Pharmaceuticals, has driven Sanofi's third-quarter performance above expectations. However, Citigroup predicts that Dupixent's sales growth will slow from 32% this year to 12% by 2027, and it expects that pricing advantages will no longer drive growth after 2027. Citigroup has raised Sanofi's target price from €78 to €93.

This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.

You may also like

iconiconiconiconiconiconiconiconicon
Customer Support:@weikecs
Business Cooperation:@weikecs
Quant Trading & MM:[email protected]
VIP Program:[email protected]